Braveheart Bio, Inc. Common Stock (BRVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Braveheart Bio, Inc. Common Stock (BRVE) has a cash flow conversion efficiency ratio of 0.177x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.95 Million) by net assets ($-95.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Braveheart Bio, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Braveheart Bio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2025–2025)
This chart illustrates how Braveheart Bio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Braveheart Bio, Inc. Common Stock (BRVE) share price today for real-time trading data and today's change.
Braveheart Bio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Braveheart Bio, Inc. Common Stock ranked by their cash flow conversion efficiency. Review Braveheart Bio, Inc. Common Stock (BRVE) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LANXESS AG UNSP.ADR 1/5
F:LX9B
|
0.013x |
|
Shenzhen Hymson Laser Intelligent Equipments Co Ltd
SHG:688559
|
0.057x |
|
BBMG Corp Class A
SHG:601992
|
-0.025x |
|
SoftwareONE Holding AG
SW:SWON
|
0.185x |
|
S&T Bancorp Inc
NASDAQ:STBA
|
0.020x |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
0.032x |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
-0.028x |
|
NCAB Group
ST:NCAB
|
0.199x |
Annual Cash Flow Conversion Efficiency for Braveheart Bio, Inc. Common Stock (2025–2025)
The table below shows the annual cash flow conversion efficiency of Braveheart Bio, Inc. Common Stock from 2025 to 2025. Also see BRVE asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-65.87 Million | $-2.01 Million | 0.031x | -- |
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is he… Read more